No evidence of cardiotoxicity during antimalarial treatment with artemether-lumefantrine.
Artemether-lumefantrine is a new fixed antimalarial combination effective against multidrug-resistant falciparum malaria. A prospective electrocardiographic study was conducted in 150 patients receiving artemetherlumefantrine and 50 treated with artesunate-mefloquine. There was no evidence for clinically significant changes in the electrocardiographic intervals and in particular no relationship between plasma concentrations of lumefantrine and QTc prolongation. Artemether-lumefantrine does not have significant cardiac effects at therapeutic doses.
van Vugt
M
M
Shoklo Malaria Research Unit, Mae Sod, Thailand.
Ezzet
F
F
Nosten
F
F
Gathmann
I
I
Wilairatana
P
P
Looareesuwan
S
S
White
N J
NJ
D000293:Adolescent; D000328:Adult; D000962:Antimalarials / Q000009:adverse effects / Q000097:blood / Q000494:pharmacology*; D000077549:Artemether; D037621:Artemisinins; D002648:Child; D002675:Child, Preschool; D004359:Drug Therapy, Combination; D004562:Electrocardiography / Q000187:drug effects; D004983:Ethanolamines / Q000009:adverse effects / Q000097:blood / Q000494:pharmacology*; D005260:Female; D005449:Fluorenes / Q000009:adverse effects / Q000097:blood / Q000494:pharmacology*; D006321:Heart / Q000187:drug effects*; D006801:Humans; D000078102:Lumefantrine; D016778:Malaria, Falciparum / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012717:Sesquiterpenes / Q000009:adverse effects / Q000494:pharmacology*
D000962:Antimalarials; D037621:Artemisinins; D004983:Ethanolamines; D005449:Fluorenes; D012717:Sesquiterpenes; D000077549:Artemether; D000078102:Lumefantrine